Pao Ling Fu Chin Biotech Co., Ltd.: Q1 2026 EPS 0.60 NTD
NQ Score
0/100
N1 Content Completeness
0
AI Summary (NQ-processed)
Pao Ling Fu Chin Biotech Co., Ltd. reported a stable performance in Q1 2026, with an EPS of 0.60 NTD, operating revenue of 519 million NTD, and net income after tax of 52 million NTD. This reaffirms its position in the biotechnology and medical industry.